Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Researchers identified hundreds of molecular markers in saliva associated with systemic pathological processes beyond the oral cavity. These markers can reflect genetic heritability of diseases such as prostate cancer, coronary disease, and Type 2 diabetes.
Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models. The findings provide insight into how different classes of FOXA1 mutations operate, shedding light on the complex mechanisms driving prostate cancer progression.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A landmark study found that the tumour immune microenvironment plays a critical role in the progression of nasopharyngeal carcinoma, paving the way for precision oncology approaches. The study discovered distinct molecular differences between NPC subtypes, which influence disease progression and treatment responsiveness.
Dr. Fong showcases advancements in liver surgery, gene therapy, and remote surgery, aiming to make exceptional cancer surgery accessible to everyone worldwide. He also highlights the potential of AI and wearables to improve patient outcomes and enhance surgical precision.
A study by the University of California, Davis found that disposable e-cigarettes release higher amounts of toxic metals than older e-cigarettes and traditional cigarettes. The devices contain hazardous levels of neurotoxic lead, carcinogenic nickel, and antimony, posing significant health risks to users.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Researchers identified 'uncommitted' cells in neuroblastoma tumors that exhibit weaker cancer development, potentially leading to favorable outcomes for patients. These cells may help identify early diagnostic markers and novel therapeutic targets.
Researchers developed an AI tool called AAnet to characterize cancer cell diversity, identifying five distinct cell groups with different gene expression profiles. This could lead to more targeted therapies and improved patient outcomes.
A new precision oncology paper presents a case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. The WIN International Molecular Tumor Board proposed personalized treatment plans based on the tumor's unique genetic mutations, highlighting the growing role of precision oncology in guiding th...
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
Scientists at UNIGE have identified MLF2 and RBM15 as key proteins regulating chromatin remodelling, which can go awry leading to cancers and neurological disorders. These two proteins could become promising therapeutic targets for diseases linked to disrupted chromatin remodelling.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.
Two Purdue researchers received funding to advance university innovations. Andrew Mesecar aims to develop new treatments for hepatocellular carcinoma using patented enzyme inhibitors. Meanwhile, Pablo Zavattieri is working on a patent-pending system to address saltwater intrusion in the Panama Canal.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
Researchers at UCLA have discovered a chromatin-based strategy that enables cells to rapidly produce proteins when nutrients are scarce. This 'priming' mechanism, driven by the MYC gene, allows cancer cells to adapt and survive under metabolic stress.
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
Researchers at University of Cologne have discovered a previously unknown mechanism that explains why many patients with aggressive B-cell lymphoma don't respond to CAR-T cell therapy. Combining this innovative treatment with CSF1R inhibitors improves its effectiveness, according to the study published in Cancer Cell.
Recent CAR-T cell modification strategies have enhanced recognition, immunity stimulation, killing activity, and safety. The new designs counteract tumor immune escape and immunosuppressive microenvironments.
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Researchers review classification, mechanisms of action and clinical application of bispecific antibodies in treating non-small cell lung cancer. Bispecific antibodies demonstrate improved anti-tumor efficacy and a safe profile for NSCLC patients resistant to targeted therapies or immune checkpoint inhibitors.
Cancer patients treated with immune checkpoint inhibitors are at risk of heart damage due to rapid loss of protective immune cells. Researchers found a biomarker, CD69, can predict which patients are most at risk and may help doctors monitor them more closely.
Researchers at UCL found that low-risk thyroid cancer patients can safely forego radioactive iodine treatment after surgery, allowing them to spend more time with family. This could impact hundreds of thousands of people worldwide, particularly younger parents and those living in the UK.
The mitochondrial ribosomal protein family (MRPs) is dysregulated in various cancers, influencing tumor initiation and progression. MRPs regulate metabolic reprogramming of immune cells within the tumor microenvironment, affecting growth, migration, invasion, and chemoresistance.
The study highlights the importance of pro-inflammatory cytokines and CXC chemokines in tumor development and immune system modulation. Age-related changes in the tumor microenvironment, including extracellular matrix stiffening and inflammatory immune mediator accumulation, contribute to tumor growth, metastasis, and immune evasion.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.
Certain dietary patterns, such as high-salt foods and processed meats, create an environment conducive to GC development. Beneficial bacteria like Akkermansia muciniphila help protect against cancer by strengthening the immune response and maintaining healthy stomach conditions.
Boston College researchers create MapID-tRNA-seq, a method to map chemical modifications and expression of human transfer RNA. The study reveals that tRNA expressions are largely dysregulated in cancerous cells compared to benign cells.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at the University of Mississippi have discovered a sea cucumber sugar compound that effectively blocks Sulf-2, an enzyme crucial for cancer growth. The compound may be easier to create and safer to use than traditional medications, with potential benefits for natural cancer therapy.
A study on long-lived bats found that they possess robust tumor-suppressor mechanisms that protect against cancer. The researchers discovered that increased activity of the p53 gene is a key defense against cancer, and that safely increasing telomerase enzyme activity could be a way to apply their findings to humans.
The Open Access Team, led by Sergei Kurenov, rides to support cancer research and honor Dr. Mikhail Blagosklonny's legacy through open-access publishing. Impact Journals is sponsoring the team in this year's Ride for Roswell event.
Researchers at Osaka Metropolitan University discovered a new way to block cancer cell energy production by suppressing de novo fatty acid synthesis with ethyl p-methoxycinnamate. This natural substance inhibits ATP production, leading to increased glycolysis as a possible survival mechanism in tumor cells.
Dr. Stephen Ross's groundbreaking studies using psilocybin therapy have demonstrated rapid, substantial, and sustained improvements in psychological symptoms for patients with advanced cancer, substance use disorders, and major depressive disorder. His research has the potential to challenge conventional psychiatric medication approaches.
Experts from the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition gathered in Nairobi, Kenya to update NCCN Clinical Practice Guidelines in Oncology for Sub-Saharan Africa. The meeting aimed to improve cancer care in the region by sharing evidence-based recommendations.
A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
The Canadian Indigenous Nurses Association and the Ontario Institute for Cancer Research are partnering to improve cancer research with Indigenous communities. The partnership aims to address unique cancer-related priorities of First Nations, Inuit, and Métis populations by supporting training and advancement of Indigenous researchers....
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
A state Medigap guaranteed issue protection was associated with a higher rate of switching to traditional Medicare among newly diagnosed cancer patients. This finding suggests that these regulations can facilitate a switch, especially for those who desire more flexibility in accessing care.
A real-world study found that mailed self-collection HPV tests significantly increased cervical cancer screening participation among never- and under-screened US women. Women who received the self-collection kits were more than twice as likely to participate in screening compared to those who received only a telephone reminder.
Recent advances in tissue-agnostic cancer drugs have resulted in highly effective treatments, but few are approved for children. Oncologists argue that these drugs should be licensed for all ages due to their effectiveness and fewer side effects. The researchers suggest that age-agnostic approvals could be made through analyzing electr...
Researchers found that higher McCance Brain Care Score is associated with lower risk of cardiovascular disease and three common cancers worldwide. The score evaluates physical, lifestyle, and social-emotional domains linked to brain health.
A cohort study found that obesity in childhood cancer survivors is linked to an increased risk of developing multiple subsequent neoplasms. Conversely, high levels of physical activity are associated with a reduced risk of these cancers.
A revolutionary AI model has been developed to diagnose lung cancer without relying on costly GPU servers or massive datasets. The ultra-lightweight model achieved a discrimination performance corresponding to an AUC value of 0.92, outperforming state-of-the-art large-scale AI systems.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
A Chinese Medical Journal study investigates the role of non-coding RNAs in pancreatic cancer, revealing how dysregulation of these molecules contributes to tumor growth and treatment resistance. The research highlights potential therapeutic targets for this devastating disease.
Researchers found that CBR3-AS1 and PCA3 were significantly overexpressed in gastric cancer tissues, suggesting their involvement in GC development. The study supports the use of these lncRNAs as diagnostic biomarkers.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
A new study uses preserved plants and animals from natural history museums to track pollution trends over two centuries. Researchers found significant changes in pollutant levels between specimens collected in the 19th and 20th centuries, highlighting the impact of industrial activity on human health.
A University of British Columbia-led study found that colorectal cancer survivors experience a range of long-term sexual health issues, including dyspareunia and pelvic inflammatory disease. The study highlights the need for better education and support for women after cancer.
A Rice University-led research team is working on a new approach to treat acute myeloid leukemia (AML) by targeting the energy-producing mitochondria of cancer cells. By disrupting mitochondrial function, the researchers aim to selectively kill AML cells while leaving healthy blood cells unharmed.
Researchers developed self-propelled ferroptosis nanoinducers to enhance cancer therapy by inducing programmed cell death. The nanotherapeutics exhibited enhanced diffusion and deep tumor penetration while maintaining biocompatibility.
Researchers developed a patient-derived organoid library to study chemotherapy resistance in esophageal cancer. Lab-grown mini-tumors showed increased activity in the NRF2 pathway, suggesting potential biomarkers for predicting chemotherapy resistance.